Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Lupin
Thumbnail
March 02, 2022

US FDA approval tracker: February 2022

Thumbnail
July 02, 2021

US FDA approval tracker: June

Article image
Vantage logo
May 27, 2021

Go or no go? Aducanumab’s day of reckoning

Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.

Article image
Vantage logo
July 02, 2020

Enbrel’s latest patent win? That’ll be $47bn

Article image
Vantage logo
March 05, 2020

Previous pandemic antiviral demand spike sees Biocryst jump aboard

Article image
Vantage logo
April 04, 2019

Topsy turvy times for industry’s mid and small cap stocks in the first quarter

What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.

Vantage logo
April 17, 2018

Private equity cleans up Sanofi’s failed generics foray

Vantage logo
February 15, 2018

Vantage view – Doing what's possible on drug prices

Article image
Vantage logo
January 08, 2018

Asia wins 2017’s mid-cap race

A cooling of the M&A climate allows Asia-based groups to come to the fore.

Article image
Vantage logo
January 04, 2018

What price controls? US FDA keeps focus on generic competition

Article image
Vantage logo
October 05, 2017

Back to the future for small caps, but not all benefit

Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 28, 2022

Access Valuable Insights Payer Behaviour Infographic

July 18, 2022

Medtech - Going steady

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.